Sarepta Therapeutics Inc [SRPT] stock is trading at $19.03, up 9.87%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The SRPT shares have gain 11.29% over the last week, with a monthly amount drifted -51.47%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Sarepta Therapeutics Inc [NASDAQ: SRPT] stock has seen the most recent analyst activity on June 20, 2025, when William Blair downgraded its rating to a Mkt Perform. Previously, TD Cowen downgraded its rating to Hold on June 18, 2025, and kept the price target unchanged to $24. On June 17, 2025, Wolfe Research initiated with a Peer Perform rating. Piper Sandler downgraded its rating to a Neutral but stick to its price target of $36 on June 16, 2025. Morgan Stanley downgraded its rating to a Equal-Weight. H.C. Wainwright downgraded its rating to Sell for this stock on June 16, 2025, but kept the price target unchanged to $10. In a note dated June 16, 2025, Cantor Fitzgerald downgraded an Neutral rating on this stock.
Sarepta Therapeutics Inc [SRPT] stock has fluctuated between $16.88 and $154.90 over the past year. Currently, Wall Street analysts expect the stock to reach $57 within the next 12 months. Sarepta Therapeutics Inc [NASDAQ: SRPT] shares were valued at $19.03 at the most recent close of the market. An investor can expect a potential return of 199.53% based on the average SRPT price forecast.
Analyzing the SRPT fundamentals
Sarepta Therapeutics Inc [NASDAQ:SRPT] reported sales of 2.23B for the trailing twelve months, which represents a growth of 80.15%. Gross Profit Margin for this corporation currently stands at 0.81% with Operating Profit Margin at -0.05%, Pretax Profit Margin comes in at -0.07%, and Net Profit Margin reading is -0.11%. To continue investigating profitability, this company’s Return on Assets is posted at -0.07, Equity is -0.2 and Total Capital is -0.04. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of1.18.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 17.80 points at the first support level, and at 16.57 for the second support level. However, for the 1st resistance point, the stock is sitting at 19.81, and for the 2nd resistance point, it is at 20.59.
Ratios To Look Out For
For context, Sarepta Therapeutics Inc’s Current Ratio is 4.02. As well, the Quick Ratio is 2.46, while the Cash Ratio is 0.4. Considering the valuation of this stock, the price to sales ratio is 0.84, the price to book ratio is 1.64.
Transactions by insiders
Recent insider trading involved Nicaise Claude, Director, that happened on Mar 12 ’25 when 2491.0 shares were sold. Director, Nicaise Claude completed a deal on Mar 12 ’25 to buy 2491.0 shares. Meanwhile, Director Wigzell Hans Lennart Rudolf sold 10500.0 shares on Dec 12 ’24.
